Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.50B | 4.41B | 4.65B | 4.32B | 3.86B |
| Total Depreciation and Amortization | 495.70M | 482.90M | 469.50M | 453.20M | 435.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -112.70M | 143.30M | -283.30M | 17.30M | 340.00M |
| Change in Net Operating Assets | -929.20M | -618.30M | -593.30M | -721.70M | 105.50M |
| Cash from Operations | 3.95B | 4.42B | 4.25B | 4.07B | 4.74B |
| Capital Expenditure | -851.30M | -755.90M | -807.70M | -741.80M | -674.30M |
| Sale of Property, Plant, and Equipment | 20.10M | 20.10M | 20.10M | 20.10M | -- |
| Cash Acquisitions | -16.50M | -16.50M | -8.80M | -59.90M | -54.90M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 714.20M | -1.72B | -2.09B | -2.03B | -3.91B |
| Cash from Investing | -133.50M | -2.47B | -2.88B | -2.81B | -4.64B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 843.80M | 1.47B | 1.68B | 1.69B | 1.34B |
| Repurchase of Common Stock | -4.04B | -3.63B | -3.15B | -2.97B | -2.76B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -93.80M | -- | -- | -- | -- |
| Other Financing Activities | -43.70M | -33.40M | -33.40M | -- | -- |
| Cash from Financing | -3.34B | -2.20B | -1.51B | -1.28B | -1.42B |
| Foreign Exchange rate Adjustments | 400.00K | -700.00K | 200.00K | -800.00K | -900.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 483.20M | -248.80M | -148.40M | -21.50M | -1.32B |